Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04853004
Other study ID # Covid19_7
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date December 31, 2024

Study information

Verified date October 2023
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the incidence of SARS-CoV-2 infections after vaccination, to monitor the development of SARS-CoV-2 antibody levels after vaccination and to compare this in relation to both previous health & disease, previous antibody responses and in relation to future disease occurring after vaccination.


Description:

The purpose of the study is to analyze the effect of and possible side effects of SARS-CoV2 vaccinations in the cohort study where data on sick leave, SARS-Cov2 infections and SARS-CoV2 antibody levels are well documented even before vaccination. The main outcome measures are the presence of SARS-CoV-2 (ongoing infection) and the presence of antibodies to SARS-CoV-2. For the vaccination effect, the factors that are primarily associated with protection against infection are analyzed, such as age, sex, workplace, antibody response to SARS-CoV-2 and vaccination date. The analyzes are planned to be performed with multivariate logistic regression with Relative Risk as the outcome measure. Data from the analysis of virus antibodies are planned to be performed divided into whether low, medium or high levels of antibodies occur, with the same analysis for possible association with the factors listed above.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10000
Est. completion date December 31, 2024
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Study participant who agreed to be included in the study "Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County". - Study participant who has received or will receive vaccine against Covid-19 and who gives new written consent to the study "Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations". Exclusion Criteria: - those who have not given informed consent to participate in the study In this study, no initiative is taken for vaccination. The vaccinations are carried out by the healthcare system and of course follow the established exclusion and inclusion criteria for the approved vaccines. All persons who have received the vaccine and who give written consent are eligible to be included in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
SARS-CoV2 antibody measurement
Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.

Locations

Country Name City State
Sweden Karolinska University Hospital Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Karolinska University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary SARS-CoV-2 infection Characterized by whether they are asymptomatic infections or sick leave-requiring infections. 24 months post primary vaccination
Secondary SARS-CoV-2 antibody induction Antibodies will be characterized in terms of antibody levels, which SARS-CoV-2 antigen to which the response is directed and whether the antibodies are protective or not. 24 months post primary vaccination
See also
  Status Clinical Trial Phase
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Terminated NCT04435457 - Cardiovascular Implications of COVID-19
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A
Completed NCT04369794 - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Phase 4
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Completed NCT04542850 - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 N/A
Completed NCT04382040 - A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Phase 2
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT04378582 - Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
Completed NCT04383587 - Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers N/A
Recruiting NCT04402814 - IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
Completed NCT04395924 - Maternal-foetal Transmission of SARS-Cov-2
Completed NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2
Completed NCT04425889 - COVID-19 Antibodies Among Healthcare Workers
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers